ArticleeLife2019
Complement and CD4
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- Review
- A transient receptor potential vanilloid 1-dependent corneal-trigeminal neuroinflammatory circuit promotes corneal neuropathy.Experimental & molecular medicine · 2026Article
- Systematic Druggable-Proteome-Wide Mendelian Randomization Identifies Potential Therapeutic Targets for Allergic Conjunctivitis.Translational vision science & technology · 2025Article
- Novel Tear Biomarkers in Ocular Graft Versus Host Disease Associated with Th1/Th2 Immune Responses: A Case Series and Literature Review.International journal of molecular sciences · 2025Review
- CD4+CD25- T-Cell-Secreted IFN-γ Promotes Corneal Nerve Degeneration in Diabetic Mice.Investigative ophthalmology & visual science · 2025Article
- Complement and T cell activation in transplantation.Transplantation reviews (Orlando, Fla.) · 2025Review
- Evaluation of the relationship between dry eye syndrome severity and corneal sensitivity.Arquivos brasileiros de oftalmologia · 2025Article
- Evolving therapeutic paradigms in ocular graft-versus-host disease.Eye (London, England) · 2024Article
- CD4Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Local complement activation and modulation in mucosal immunity.Mucosal immunology · 2024Review
- A Novel Murine Model for Lupus-Like Ocular Chronic Graft-Versus-Host Disease.Investigative ophthalmology & visual science · 2024Article
- Complement Suppresses the Initial Type 1 Interferon Response to Ocular Herpes Simplex Virus Type 1 Infection in Mice.Pathogens (Basel, Switzerland) · 2024Article
- The role of PPAR in fungal keratitis.Frontiers in immunology · 2024Review
- Spiral ganglion neuron degeneration in aminoglycoside-deafened rats involves innate and adaptive immune responses not requiring complement.Frontiers in molecular neuroscience · 2024Article
- Murine models of graft versus host disease (GVHD): Focus on ocular GVHD.The ocular surface · 2023Review
- Effects of Cathepsin S Inhibition in the Age-Related Dry Eye Phenotype.Investigative ophthalmology & visual science · 2023Article
- [Chinese expert consensus on ocular chronic graft-versus-host disease (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- An ocular Th1 immune response promotes corneal nerve damage independently of the development of corneal epitheliopathy.Journal of neuroinflammation · 2023Article
- Anti-inflammatory Therapy Protects Spiral Ganglion Neurons After Aminoglycoside Antibiotic-Induced Hair Cell Loss.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Recent advances in ocular graft-versus-host disease.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Whether complement dysregulation directly contributes to the pathogenesis of peripheral nervous system diseases, including sensory neuropathies, is unclear. We addressed this important question in a mouse model of ocular HSV-1 infection, where sensory nerve damage is a common clinical problem. Through genetic and pharmacologic targeting, we uncovered a central role for C3 in sensory nerve damage at the morphological and functional levels. Interestingly, CD4 T cells were central in facilitating this complement-mediated damage. This same C3/CD4 T cell axis triggered corneal sensory nerve damage in a mouse model of ocular graft-versus-host disease (GVHD). However, this was not the case in a T-dependent allergic eye disease (AED) model, suggesting that this inflammatory neuroimmune pathology is specific to certain disease etiologies. Collectively, these findings uncover a central role for complement in CD4 T cell-dependent corneal nerve damage in multiple disease settings and indicate the possibility for complement-targeted therapeutics to mitigate sensory neuropathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.